Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception

Sidney A. Edsall, Richard J. Knapp, Todd W Vanderah, William R Roeske, Paul Consroe, Henry I. Yamamura

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Studies using agonists from at least three major cannabinoid ligand groups suggest the mediation of several distinct effects (e.g. psychotropic, analgesia, and antiemetic) by the recently cloned CB1 cannabinoid receptor. However, other studies suggest the presence of multiple cannabinoid receptors and at least one other receptor (CB2) has been cloned. The present investigation was undertaken to determine whether one of the potential therapeutic actions of cannabinoids (i.e. antinociception) is mediated by the CB1 receptor using the antisense oligodeoxynucleotide 'knock-down' approach. Synthetic oligodeoxynucleotides complementary to the 5' end of the coding region of the mouse CB1 receptor mRNA were administered to mice by the intracerebroventricular (i.c.v.) route twice daily for 3 days. Mismatch oligodeoxynucleotides of similar sequence, but containing six mismatched positions out of the 18 nucleotides within the oligodeoxynucleotide were administered to other mice. Treatment with antisense oligodeoxynucleotides, but not mismatched oligodeoxynucleotides, greatly inhibited the antinociceptive response of the cannabinoid agonist CP-55,940. Untreated mice and those treated with mismatched oligodeoxynucleotides showed similar, full response antinociception after CP-55,940 administration. The data provides strong evidence that the CB1 receptor-ligand interaction is essential for the antinociceptive effect.

Original languageEnglish (US)
Pages (from-to)593-596
Number of pages4
JournalNeuroReport
Volume7
Issue number2
StatePublished - 1996

Fingerprint

Cannabinoid Receptors
Oligodeoxyribonucleotides
Cannabinoid Receptor CB1
Brain
Cannabinoids
Cannabinoid Receptor CB2
Cannabinoid Receptor Agonists
Ligands
Antiemetics
Analgesia
Action Potentials
Nucleotides
Messenger RNA

Keywords

  • antinociception
  • antisense oligeodoxynucleotides
  • cannabinoid receptor
  • CP-55,940
  • mouse

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. / Edsall, Sidney A.; Knapp, Richard J.; Vanderah, Todd W; Roeske, William R; Consroe, Paul; Yamamura, Henry I.

In: NeuroReport, Vol. 7, No. 2, 1996, p. 593-596.

Research output: Contribution to journalArticle

Edsall, Sidney A. ; Knapp, Richard J. ; Vanderah, Todd W ; Roeske, William R ; Consroe, Paul ; Yamamura, Henry I. / Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. In: NeuroReport. 1996 ; Vol. 7, No. 2. pp. 593-596.
@article{5ad2bc52ce994544a88e8a28b44ded30,
title = "Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception",
abstract = "Studies using agonists from at least three major cannabinoid ligand groups suggest the mediation of several distinct effects (e.g. psychotropic, analgesia, and antiemetic) by the recently cloned CB1 cannabinoid receptor. However, other studies suggest the presence of multiple cannabinoid receptors and at least one other receptor (CB2) has been cloned. The present investigation was undertaken to determine whether one of the potential therapeutic actions of cannabinoids (i.e. antinociception) is mediated by the CB1 receptor using the antisense oligodeoxynucleotide 'knock-down' approach. Synthetic oligodeoxynucleotides complementary to the 5' end of the coding region of the mouse CB1 receptor mRNA were administered to mice by the intracerebroventricular (i.c.v.) route twice daily for 3 days. Mismatch oligodeoxynucleotides of similar sequence, but containing six mismatched positions out of the 18 nucleotides within the oligodeoxynucleotide were administered to other mice. Treatment with antisense oligodeoxynucleotides, but not mismatched oligodeoxynucleotides, greatly inhibited the antinociceptive response of the cannabinoid agonist CP-55,940. Untreated mice and those treated with mismatched oligodeoxynucleotides showed similar, full response antinociception after CP-55,940 administration. The data provides strong evidence that the CB1 receptor-ligand interaction is essential for the antinociceptive effect.",
keywords = "antinociception, antisense oligeodoxynucleotides, cannabinoid receptor, CP-55,940, mouse",
author = "Edsall, {Sidney A.} and Knapp, {Richard J.} and Vanderah, {Todd W} and Roeske, {William R} and Paul Consroe and Yamamura, {Henry I.}",
year = "1996",
language = "English (US)",
volume = "7",
pages = "593--596",
journal = "NeuroReport",
issn = "0959-4965",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception

AU - Edsall, Sidney A.

AU - Knapp, Richard J.

AU - Vanderah, Todd W

AU - Roeske, William R

AU - Consroe, Paul

AU - Yamamura, Henry I.

PY - 1996

Y1 - 1996

N2 - Studies using agonists from at least three major cannabinoid ligand groups suggest the mediation of several distinct effects (e.g. psychotropic, analgesia, and antiemetic) by the recently cloned CB1 cannabinoid receptor. However, other studies suggest the presence of multiple cannabinoid receptors and at least one other receptor (CB2) has been cloned. The present investigation was undertaken to determine whether one of the potential therapeutic actions of cannabinoids (i.e. antinociception) is mediated by the CB1 receptor using the antisense oligodeoxynucleotide 'knock-down' approach. Synthetic oligodeoxynucleotides complementary to the 5' end of the coding region of the mouse CB1 receptor mRNA were administered to mice by the intracerebroventricular (i.c.v.) route twice daily for 3 days. Mismatch oligodeoxynucleotides of similar sequence, but containing six mismatched positions out of the 18 nucleotides within the oligodeoxynucleotide were administered to other mice. Treatment with antisense oligodeoxynucleotides, but not mismatched oligodeoxynucleotides, greatly inhibited the antinociceptive response of the cannabinoid agonist CP-55,940. Untreated mice and those treated with mismatched oligodeoxynucleotides showed similar, full response antinociception after CP-55,940 administration. The data provides strong evidence that the CB1 receptor-ligand interaction is essential for the antinociceptive effect.

AB - Studies using agonists from at least three major cannabinoid ligand groups suggest the mediation of several distinct effects (e.g. psychotropic, analgesia, and antiemetic) by the recently cloned CB1 cannabinoid receptor. However, other studies suggest the presence of multiple cannabinoid receptors and at least one other receptor (CB2) has been cloned. The present investigation was undertaken to determine whether one of the potential therapeutic actions of cannabinoids (i.e. antinociception) is mediated by the CB1 receptor using the antisense oligodeoxynucleotide 'knock-down' approach. Synthetic oligodeoxynucleotides complementary to the 5' end of the coding region of the mouse CB1 receptor mRNA were administered to mice by the intracerebroventricular (i.c.v.) route twice daily for 3 days. Mismatch oligodeoxynucleotides of similar sequence, but containing six mismatched positions out of the 18 nucleotides within the oligodeoxynucleotide were administered to other mice. Treatment with antisense oligodeoxynucleotides, but not mismatched oligodeoxynucleotides, greatly inhibited the antinociceptive response of the cannabinoid agonist CP-55,940. Untreated mice and those treated with mismatched oligodeoxynucleotides showed similar, full response antinociception after CP-55,940 administration. The data provides strong evidence that the CB1 receptor-ligand interaction is essential for the antinociceptive effect.

KW - antinociception

KW - antisense oligeodoxynucleotides

KW - cannabinoid receptor

KW - CP-55,940

KW - mouse

UR - http://www.scopus.com/inward/record.url?scp=0029868795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029868795&partnerID=8YFLogxK

M3 - Article

C2 - 8730837

AN - SCOPUS:0029868795

VL - 7

SP - 593

EP - 596

JO - NeuroReport

JF - NeuroReport

SN - 0959-4965

IS - 2

ER -